Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen - PubMed (original) (raw)

Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen

S Imai et al. Oncology. 1990.

Abstract

A cultured cell line (SHIN-3) derived from a human ovarian serous cystadenocarcinoma which consistently produces two tumor markers, CA-125 and tissue polypeptide antigen (TPA) was established. After 1 week of culture of 1 x 10(5) cells, high levels of tumor marker were observed (the total CA-125 release was 1,500 U and the total TPA release was 37.5 U). Expression of CA-125 and TPA was also demonstrated in cultured cells immunohistochemically. The volume of CA-125 release per cell was highest just before the start of the logarithmic growth phase. TPA production was increased in the logarithmic growth phase, but its relationship to the total number of cells was not clear.

PubMed Disclaimer

Similar articles

• Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
  Fukazawa I, Inaba N, Ota Y, Sato N, Shirotake S, Iwasawa H, Sekiya S, Takamizawa H, Suzuki N, Tokita H. Fukazawa I, et al. Arch Gynecol Obstet. 1988;243(2):69-81. doi: 10.1007/BF00932972. Arch Gynecol Obstet. 1988. PMID: 3165255
• [Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer].
  Negishi Y, Furuno K, Sano Y, Hirata T, Utsunomiya A, Nakajima H, Okabe K, Shimizu K, Akiya K, Fujiwara Y. Negishi Y, et al. Gan No Rinsho. 1985 May;31(6 Suppl):655-63. Gan No Rinsho. 1985. PMID: 2993692 Japanese.
• [Establishment and characterization of a human ovarian adenocarcinoma cell line OC-8611].
  Huang JS. Huang JS. Zhonghua Zhong Liu Za Zhi. 1989 Nov;11(6):416-8. Zhonghua Zhong Liu Za Zhi. 1989. PMID: 2634538 Chinese.
• [Biological properties of two newly established cell lines (RMUG-S, RMUG-L) from a human ovarian mucinous cystadenocarcinoma].
  Sakayori M, Nozawa S, Udagawa Y, Chin K, Lee SG, Sakuma T, Iizuka R, Wada Y, Yoshida S, Takeda Y. Sakayori M, et al. Hum Cell. 1990 Mar;3(1):52-6. Hum Cell. 1990. PMID: 2083224 Japanese.
• Transforming growth factor-alpha promotes tumor markers secretion from human ovarian cancers in vitro.
  Kurachi H, Adachi H, Morishige K, Adachi K, Takeda T, Homma H, Yamamoto T, Miyake A. Kurachi H, et al. Cancer. 1996 Sep 1;78(5):1049-54. doi: 10.1002/(SICI)1097-0142(19960901)78:5<1049::AID-CNCR15>3.0.CO;2-2. Cancer. 1996. PMID: 8780543

Cited by

• Characterisation and clinical usefulness of CA130 antigen recognised by monoclonal antibodies, 130-22 and 145-9, in ovarian cancers.
  Kobayashi H, Ohi H, Fujii T, Terao T. Kobayashi H, et al. Br J Cancer. 1993 Feb;67(2):237-43. doi: 10.1038/bjc.1993.46. Br J Cancer. 1993. PMID: 7679280 Free PMC article.
• Sensitive β-galactosidase-targeting fluorescence probe for visualizing small peritoneal metastatic tumours in vivo.
  Asanuma D, Sakabe M, Kamiya M, Yamamoto K, Hiratake J, Ogawa M, Kosaka N, Choyke PL, Nagano T, Kobayashi H, Urano Y. Asanuma D, et al. Nat Commun. 2015 Mar 13;6:6463. doi: 10.1038/ncomms7463. Nat Commun. 2015. PMID: 25765713 Free PMC article.
• Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases.
  Ogawa M, Kosaka N, Longmire MR, Urano Y, Choyke PL, Kobayashi H. Ogawa M, et al. Mol Pharm. 2009 Mar-Apr;6(2):386-95. doi: 10.1021/mp800115t. Mol Pharm. 2009. PMID: 19718793 Free PMC article.
• Molecular design strategy of fluorogenic probes based on quantum chemical prediction of intramolecular spirocyclization.
  Tachibana R, Kamiya M, Suzuki S, Morokuma K, Nanjo A, Urano Y. Tachibana R, et al. Commun Chem. 2020 Jun 26;3(1):82. doi: 10.1038/s42004-020-0326-x. Commun Chem. 2020. PMID: 36703479 Free PMC article.
• In search of specific cytotoxic T lymphocytes infiltrating or accompanying human ovarian carcinoma.
  Apiranthitou-Drogari M, Paganin C, Bernasconi S, Losa G, Maneo A, Colombo N, Mantovani A, Allavena P. Apiranthitou-Drogari M, et al. Cancer Immunol Immunother. 1992;35(4):289-95. doi: 10.1007/BF01789337. Cancer Immunol Immunother. 1992. PMID: 1387344 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • S. Karger AG, Basel, Switzerland

• Medical

  • MedlinePlus Health Information

• Research Materials

  • Cellosaurus - a cell line knowledge resource
  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal